Digoxin Prescription Emerges as Key Player in Enhancing Survival after Hybrid Stage 1 Palliation in infants: Study

Written By : Dr.Niharika Harsha B |Medically Reviewed By : Dr. Kamal Kant Kohli Published On 2024-04-26T22:00:37+05:30 | Updated On 27 April 2024 11:44 AM IST

In a groundbreaking development in pediatric cardiology, a recent study has unveiled the positive impact of digoxin prescription on the transplant-free interstage survival of infants with single-ventricle physiology following hybrid stage 1 palliation. The analysis found that for infants with single-ventricle physiology who underwent hybrid stage 1 palliation, the digoxin prescription at hospital discharge is linked to improved transplant-free interstage survival.

The research, conducted using data from the National Pediatric Cardiology Quality Improvement Collaborative registry spanning over a decade, challenges conventional practices and offers a promising avenue for improving outcomes in a vulnerable population. The study results were published in the Journal of the American Heart Association.

Also Read: Digoxin or bisoprolol did not improve quality of life in AF patients with HF: JAMA

The administration of digoxin to individuals with single-ventricle physiology post-stage 1 palliation has been linked to a decrease in interstage mortality. Previous research has predominantly focused on patients who underwent the Norwood procedure. Hence, researchers conducted a study to investigate whether prescribing digoxin upon discharge for infants following hybrid stage 1 palliation was correlated with enhanced transplant-free interstage survival.

Conducting a retrospective multicenter cohort analysis using data from the National Pediatric Cardiology Quality Improvement Collaborative registry spanning from 2008 to 2021, this study focused on infants with functional single ventricles and aortic arch obstruction discharged after hybrid stage 1 palliation. Exclusions were made for patients with supraventricular tachycardia or conversion to the Norwood operation. The primary outcome measured was transplant-free survival.

Findings:

Involving 259 infants from 45 sites, including 158 with hypoplastic left heart syndrome, the study observed that 50% of subjects were discharged on digoxin.

The incidence of interstage death or transplant was 23% in the no-digoxin group compared to 14% in the digoxin group (P=0.06).

Multivariate analysis, incorporating a propensity score for digoxin use, revealed that discharge digoxin prescription was associated with a lower risk of interstage death or transplant.

The study's conclusions signify a pivotal moment in pediatric cardiology, suggesting that digoxin prescription at hospital discharge could be a game-changer for infants undergoing hybrid stage 1 palliation. The positive association with improved transplant-free interstage survival emphasizes the need for a reevaluation of postoperative care strategies in this specific cohort.

Also Read: Linaclotide Proves Effective for Pediatric Constipation

Take home points: Through the analysis of data from a multicenter clinical registry, infants with single-ventricle heart defects who received digoxin prescriptions at the time of hospital discharge after undergoing stage 1 hybrid palliation exhibited elevated transplant-free survival during the interstage period. These results align with prior studies involving the stage 1 Norwood operation, indicating that the proactive use of digoxin may be a reasonable approach during the interstage period for infants who have undergone the stage 1 hybrid palliation procedure.

Further reading: Reddy RK, Zyblewski SC, Chowdhury SM, et al. Association of Digoxin Use With Transplant-Free Interstage Survival in Infants Palliated With a Stage 1 Hybrid Procedure. J Am Heart Assoc. 2023;12(20):e029521. doi:10.1161/JAHA.123.029521

Journal of the American Heart AssociationJAHAReshma K. ReddyDigoxinStage 1 Hybrid Procedure

Source : Journal of the American Heart Association

Dr.Niharika Harsha B

BDS, MDS

Dr.Niharika Harsha B (BDS,MDS) completed her BDS from Govt Dental College, Hyderabad and MDS from Dr.NTR University of health sciences(Now Kaloji Rao University). She has 4 years of private dental practice and worked for 2 years as Consultant Oral Radiologist at a Dental Imaging Centre in Hyderabad. She worked as Research Assistant and scientific writer in the development of Oral Anti cancer screening device with her seniors. She has a deep intriguing wish in writing highly engaging, captivating and informative medical content for a wider audience. She can be contacted at editorial@medicaldialogues.in.

Dr. Kamal Kant Kohli

Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751